前列腺癌(PCa)是中老年男性多发癌症之一,目前针对晚期转移性患者的主要治疗手段是去雄激素治疗,但是绝大部分患者最终都进展为侵袭性更强的激素非依赖型PCa,而对此类患者尚无有效治疗方法。雄激素受体(AR)是前列腺上皮细胞分化与增生的基本调节因子,在调控PCa细胞存活机制方面具有非常重要作用。目前的研究结果已经表明在激素非依赖型PCa进展过程中,AR的非正常激活是关键性因素。现简要综述AR调控的PCa细胞存活机制以及针对它而设计的RNA干扰技术对PCa的治疗运用方面的进展。 Prostate cancer (PCa) is one of the most common cancers in middle-aged and elderly men. So far the main treatment for advanced metastatic patients is androgen therapy. However, most patients eventually progress to the more aggressive hormone-independent PCa. There is no effective treatment for such patients. Androgen receptor (AR) is a basic regulator of prostate epithelial cell differentiation and proliferation and plays a very important role in regulating the survival mechanism of PCa cells. The current results have shown that the abnormal activation of AR is the key factor in the progression of hormone-independent PCa. This review summarizes the progress of AR-controlled PCa cell survival and the therapeutic application of RNA interference designed to treat PCa.